"Ectoparasites have never been exposed to this new molecule," according to Dr. Albert Ahn. The original research work on Vectra 3D was conducted by the founding employees of Summit VetPharm who are all veterinary professionals. The development work was funded by Sumitomo Corporation and all registrations and patents are now owned by Summit VetPharm. Vectra 3D, containing Dinotefuran was developed exclusively for the veterinary channel. With the exclusive rights to Vectra 3D and Dinotefuran in the companion animal market Summit VetPharm holds the EPA Registration No. 83399-6 for Vectra 3D, and is the sole owner of the federal and state registrations and all patents associated with the Vectra 3D product.
In studies conducted both in the laboratory and in the field, Vectra 3D has shown no clinically significant treatment-related adverse events, and exhibits a rapid knockdown effect.
"Vectra 3D has demonstrated remarkable speed of kill and reinfestation protection in all weight ranges of dogs," according to Dr. Ahn. Vectra 3D kills 96 percent of adult fleas within six hours, 100% within 12 hours, repels other fleas from attaching to the dog and prevents development of flea eggs, larvae and pupae. It also repels and kills four species of ticks (Black- legged Deer tick, Brown Dog tick, American Dog tick and Gulf Coast tick) and three species of mosquitoes (Culex spp., Ochlerotatus spp. and Aedes spp.)
"With the increased threat of vector borne diseases, the ability to kill and repel these parasites is extremely important. Vectra 3D kills the vectors that can cause Lyme disease, Rocky Mountain Spotted fever, babesiosis, ehrlichiosis, bartonellosis, hepatozoonosis, tapeworm and heartworm disease," explains Dr. Ahn.
"The last decade has seen remarkable advancements in animal healthcare,
and Summit VetPharm looks to further extend the range of beneficial
veterinary pharmaceutical options for companion animals", said Stephanus.
|SOURCE Sumitomo Corporation of America|
Copyright©2007 PR Newswire.
All rights reserved